Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT PromoterNeuro-oncology 2022 May 02;[EPub Ahead of Print], M Lim, M Weller, A Idbaih, J Steinbach, G Finocchiaro, RR Raval, G Ansstas, J Baehring, JW Taylor, J Honnorat, K Petrecca, F De Vos, A Wick, A Sumrall, S Sahebjam, IK Mellinghoff, M Kinoshita, M Roberts, R Slepetis, D Warad, D Leung, M Lee, DA Reardon, A Omuro
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.